Lahar Mehta

1.6k total citations
36 papers, 1.1k citations indexed

About

Lahar Mehta is a scholar working on Pathology and Forensic Medicine, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Lahar Mehta has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 10 papers in Psychiatry and Mental health and 7 papers in Molecular Biology. Recurrent topics in Lahar Mehta's work include Multiple Sclerosis Research Studies (14 papers), Migraine and Headache Studies (9 papers) and Peripheral Neuropathies and Disorders (6 papers). Lahar Mehta is often cited by papers focused on Multiple Sclerosis Research Studies (14 papers), Migraine and Headache Studies (9 papers) and Peripheral Neuropathies and Disorders (6 papers). Lahar Mehta collaborates with scholars based in United States, United Kingdom and Switzerland. Lahar Mehta's co-authors include David Shprecher, Roger Cady, Jacob Elkins, Steven R. Schwid, Joe Hirman, Robert H. Dworkin, Aneesh B. Singhal, Ih Chang, Sarah Gheuens and Mitchell S.V. Elkind and has published in prestigious journals such as JAMA, Neurology and The Lancet Neurology.

In The Last Decade

Lahar Mehta

35 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lahar Mehta United States	17	586	343	278	196	180	36	1.1k
Ernestina Santos Portugal	19	455 0.8×	111 0.3×	380 1.4×	152 0.8×	115 0.6×	86	1.3k
Fereshteh Ashtari Iran	17	634 1.1×	203 0.6×	209 0.8×	49 0.3×	87 0.5×	82	952
J. H. Aarseth Norway	14	335 0.6×	85 0.2×	134 0.5×	132 0.7×	96 0.5×	18	759
Nebojša Stojsavljević Serbia	19	702 1.2×	143 0.4×	218 0.8×	80 0.4×	136 0.8×	34	1.0k
Erna Harboe Norway	19	187 0.3×	203 0.6×	175 0.6×	48 0.2×	104 0.6×	27	1.1k
Filipe Palavra Portugal	12	592 1.0×	68 0.2×	235 0.8×	43 0.2×	147 0.8×	44	921
Laura Edwards United Kingdom	15	290 0.5×	67 0.2×	71 0.3×	60 0.3×	150 0.8×	35	835
Andreia Bettencourt Portugal	18	264 0.5×	83 0.2×	92 0.3×	54 0.3×	84 0.5×	39	761
Amir Hadi Maghzi Iran	11	260 0.4×	44 0.1×	113 0.4×	74 0.4×	245 1.4×	23	680
KG Simon United States	6	746 1.3×	126 0.4×	77 0.3×	24 0.1×	104 0.6×	9	981

Countries citing papers authored by Lahar Mehta

Since Specialization

Citations

This map shows the geographic impact of Lahar Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lahar Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lahar Mehta more than expected).

Fields of papers citing papers by Lahar Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lahar Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lahar Mehta. The network helps show where Lahar Mehta may publish in the future.

Co-authorship network of co-authors of Lahar Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Lahar Mehta. A scholar is included among the top collaborators of Lahar Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lahar Mehta. Lahar Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bowser, Robert, Jiyan An, Lahar Mehta, et al.. (2023). Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial. Journal of Neurology Neurosurgery & Psychiatry. 95(7). 605–608. 11 indexed citations

Martin, Vincent T., Marina Janelidze, Joe Hirman, et al.. (2022). Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. Clinical Therapeutics. 44(3). 389–402. 13 indexed citations

McAllister, Peter, Paul Winner, Jessica Ailani, et al.. (2022). Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. The Journal of Headache and Pain. 23(1). 22–22. 8 indexed citations

Smith, Timothy R., Egilius L.H. Spierings, Roger Cady, et al.. (2021). Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. The Journal of Headache and Pain. 22(1). 16–16. 34 indexed citations

McAllister, Peter, Jessica Ailani, Lahar Mehta, et al.. (2021). P.027 Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48(s3). S27–S28.

Lipton, Richard B., David W. Dodick, Jessica Ailani, et al.. (2020). Patient-Identified Most Bothersome Symptom in Patients with Chronic Migraine: An Analysis of PROMISE-2 (541). Neurology. 94(15_supplement). 1 indexed citations

Hauser, Stephen L., Ludwig Kappos, Douglas L. Arnold, et al.. (2020). Five years of ocrelizumab in relapsing multiple sclerosis. Neurology. 95(13). e1854–e1867. 106 indexed citations

Hauser, Stephen L., Ludwig Kappos, Xavier Montalbán, et al.. (2019). Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (P3.2-054). Neurology. 92(15_supplement). 1 indexed citations

Arnold, Douglas L., Gavin Giovannoni, Hans‐Peter Hartung, et al.. (2019). Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up (P3.2-042). Neurology. 92(15_supplement). 1 indexed citations

10.

Giovannoni, Gavin, Ludwig Kappos, Stephen L. Hauser, et al.. (2019). Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Journal of the Neurological Sciences. 405. 308–309. 4 indexed citations

11.

Elkins, Jacob, Roland Veltkamp, Joan Montaner, et al.. (2017). Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology. 16(3). 217–226. 160 indexed citations

12.

Hobart, Jeremy, Tjalf Ziemssen, Peter Feys, et al.. (2017). Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial (P6.364). Neurology. 88(16_supplement). 3 indexed citations

13.

Gasperini, Claudio, Raymond Hupperts, Jan Lycke, et al.. (2016). Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. Journal of the Neurological Sciences. 370. 123–131. 10 indexed citations

14.

McNeill, Liz, et al.. (2014). Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment. Value in Health. 17(7). A401–A402. 1 indexed citations

15.

Havrdová, Eva, Gavin Giovannoni, Dusan Stefoski, et al.. (2013). Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study (P07.105). Neurology. 80(7_supplement). 2 indexed citations

16.

Giovannoni, Gavin, Ernst‐Wilhelm Radue, Eva Havrdová, et al.. (2013). Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. Journal of Neurology. 261(2). 316–323. 17 indexed citations

17.

Shprecher, David & Lahar Mehta. (2010). The syndrome of delayed post-hypoxic leukoencephalopathy.. PubMed. 26(1). 65–72. 73 indexed citations

18.

Mehta, Lahar, Robert H. Dworkin, & Steven R. Schwid. (2009). Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nature Clinical Practice Neurology. 5(2). 82–92. 52 indexed citations

19.

Mehta, Lahar, Michael McDermott, Andrew Goodman, & Steven R. Schwid. (2009). A randomized trial of memantine as treatment for spasticity in multiple sclerosis. Multiple Sclerosis Journal. 16(2). 248–251. 7 indexed citations

20.

Mehta, Lahar, Elaine Skalabrin, James B. Burns, et al.. (2008). Sporadic Fatal Insomnia Masquerading as a Paraneoplastic Cerebellar Syndrome. Archives of Neurology. 65(7). 971–3. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact